Is ExxonMobil a Buy?
The oil giant has a long-term plan to enrich its investors.
Estee Lauder Hands in a Nearly Blemish-Free Earnings Report
The beauty giant closed out fiscal 2019 with palpable momentum while forecasting a vigorous year ahead.
Wearables Are Moving the Needle for Apple
As demand for the flagship iPhone continues to stagnate, other products and services are picking up the slack.
Shares of the graphics-chip specialist got a boost from several catalysts, including the company's announcement of a big win in its gaming business.
Here's one boring, likely answer and two speculative ones.
Payroll taxes are taken out of your paycheck -- but what exactly are these taxes and how much are you paying for them?
These marijuana stocks are delivering eye-opening growth, and they should be on your radar.
A new credit card exclusive to Apple customers is getting a lot of hype.
The possibility of pot stocks writing down the value of their goodwill is growing.
When peers warn about slowing end markets, it's usually a good idea to take heed.
Shares of the fashion retail giant have fallen out of style over the past year, but investors may be underestimating Nordstrom's long-term earnings potential.
AT&T, Verizon, T-Mobile, and Sprint are not the only choices when picking a wireless plan. Is making the switch to prepaid the right option for you?
Investors have run back to the stock after promising clinical results.
Some stocks you merely buy. Others are at the core of your portfolio. These three belong in the latter category.
A simple assessment could lead you to the right filing decision.
The company still isn't making money, but it's making progress.
Netflix, Cintas, and Boston Beer are companies with businesses that are easy to grasp.
It's really about what Buffett didn't do in the second quarter that's so shocking.
Canadian Solar's earnings report showed some positive signs for the solar industry.
The charts for these three stocks show the kinds of curves that investors should really like -- trending upward.
The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.
Former Canopy Growth co-CEO Bruce Linton says that he's taking advantage of the stock's big sell-off to buy shares. Should investors follow his lead?
WeWork insists it’s worth tech company hype and valuation but doesn’t back it up.